Begin main content

Search

We found 41 result(s) for "pembrolizumab"

Metastatic Melanoma Gap Analysis

Last Updated: June 8, 2018
Result type: Reports
Product Line: Technology Review

The CADTH pCODR Expert Review Committee (pERC) has issued reimbursement recommendations on immunotherapies (ipilimumab, pembrolizumab, nivolumab, and nivolumab plus ipilimumab) and BRAF mutation targeted therapies (dabrafenib plus trametinib, dabrafenib, vemurafenib, and vemurafenib plus cobimetinib) for the treatment of metastatic melanoma. Alt...

  • Project Number: HE0004-000